What is the translation of " NUSPOJAVE OPAŽENE " in English?

• adverse reactions observed
• adverse reactions seen

Examples of using Nuspojave opažene in Croatian and their translations into English

Nuspojave opažene uz Aerius.
Adverse reactions seen with Aerius.

U Tablici 1 prikazane su nuspojave opažene iz spontanih prijava i u placebom kontroliranim kliničkim ispitivanjima.
Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials.

Nuspojave opažene uz Azomyr.
Adverse reactions seen with Azomyr.

Tablica 1: Nuspojave opažene objedinjenim pivotalnim kontroliranim ispitivanjima faze 3.
Table 1: Adverse reactions observed in pooled pivotal phase 3 controlled clinical studies.

Nuspojave opažene uz Aerinaze.
Adverse reactions seen with Aerinaze.

Tablica 6: Nuspojave opažene u pedijatrijskih bolesnika s teškim oblikom osteogenesis imperfecta1.
Table 6: Adverse reactions observed in paediatric patients with severe osteogenesis imperfecta1.

Nuspojave opažene uz Neoclarityn.
Adverse reactions seen with Neoclarityn.

Tablica 1 prikazuje nuspojave opažene u kliničkim ispitivanjima u 71 bolesnika u dobi od 1 dana do 66 godina.
Table 1 gives the adverse reactions observed from clinical trials in 71 patients age 1 day to 66 years.

Nuspojave opažene uz Desloratadin Teva.
Adverse reactions seen with desloratadine.

Tablica 3 prikazuje nuspojave opažene u kliničkim ispitivanjima u bolesnika s melanomom liječenih lijekom Imlygic u usporedbi s GM-CSF.
Table 3 presents the adverse reactions observed in clinical trials in patients with melanoma treated with Imlygic compared to GM-CSF.

Nuspojave opažene u kliničkim istraživanjima.
Side effects seen in clinical trials.

Najčešće prijavljene nuspojave opažene u kliničkim ispitivanjima su omaglica, glavobolja, krvarenje, mučnina, krvarenje na mjestu uboda u venu, krvarenje nakon zahvata i iscjedak iz rane.
The most commonly reported adverse reactions observed in clinical trials are dizziness, headache, haemorrhage, nausea, venipuncture site haemorrhage, post procedural haemorrhage and wound secretion.

Nuspojave opažene kod monoterapije KE.
Adverse reactions that have been observed with CE monotherapy.

U tablici 1 navedene su nuspojave opažene uz ivakaftor u kliničkim ispitivanjima(placebom kontroliranim i nekontroliranim ispitivanjima) u kojima se izloženost ivakaftoru kretala u rasponu od 16 tjedana do 144 tjedna.
Table 1 reflects the adverse reactions observed with ivacaftor in clinical trials(placebo-controlled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks.

Nuspojave opažene kod istodobne primjene fenofibrata i simvastatina Cholib.
Adverse reactions observed with the co-administration of fenofibrate and simvastatin Cholib.

U tablici u nastavku(tablica 1) navedene su nuspojave opažene u analizi objedinjenih podataka iz pivotalnih kontroliranih ispitivanja faze 3 u kojima je alogliptin ispitan kao monoterapija i kao dodatna kombinirana terapija, a uključivala su 5.659 bolesnika.
In the pooled pivotal phase 3 controlled clinical trials of alogliptin as monotherapy and as add-on combination therapy involving 5,659 patients, the observed adverse reactions are listed below Table 1.

Nuspojave opažene uz Xofigo prikazane su u tablici niže vidjeti Tablicu 1.
The adverse reactions observed with Xofigo are represented in the table below see Table 1.

Tablica 3: Nuspojave opažene u kliničkim ispitivanjima u bolesnika s melanomom liječenih lijekom Imlygic.
Table 3: Adverse reactions observed in clinical trials in patients with melanoma treated with Imlygic.

Za nuspojave opažene s više od jedne komponente fiksne kombinacije doza, najviša učestalost je navedena u tablici u nastavku.
For adverse reactions observed with more than one component of a fixed-dose combination, the highest frequency is listed in the table below.

Nuspojave opažene s Rasilez HCT-om ili u monoterapiji s jednom ili svakom od dvije komponente uključene su u tablici u nastavku.
The adverse reactions observed with Rasilez HCT or with monotherapy with one or both of the two components are included in the table below.

Nuspojave opažene u bolesnika liječenih apremilastom navedene su u nastavku prema klasifikaciji organskih sustava i učestalosti svih nuspojava.
The adverse reactions observed in patients treated with apremilast are listed below by system organ class(SOC) and frequency for all adverse reactions..

Tablica 1: Nuspojave opažene tijekom kliničkih ispitivanja u kojima je Fexeric primijenjen u bolesnika s KBB 5D na hemodijalizi ili peritonejskoj dijalizi.
Table 1: Adverse reactions observed during clinical studies in which Fexeric was administered in CKD 5D patients on haemodialysis or peritoneal dialysis.

C Nuspojave opažene s Rasilamlom; a Nuspojave opažene u monoterapiji s aliskirenom; am Nuspojave opažene u monoterapiji s amlodipinom;
C Adverse reaction observed with Rasilamlo; a Adverse reaction observed with monotherapy with aliskiren; am Adverse reaction observed with monotherapy with amlodipine;

Ozbiljne nuspojave opažene češće(≥ 5%) za lenalidomid u kombinaciji s niskom dozom deksametazona(Rd i Rd18) nego za melfalan, prednizon i talidomid(MPT) bile su.
The serious adverse reactions observed more frequently(≥5%) with lenalidomide in combination with low dose dexamethasone(Rd and Rd18) than with melphalan, prednisone and thalidomide(MPT) were.

Dodatne nuspojave opažene kod primjene doza izvan preporučenih razina i indikacije tj. primijenjenih kod CTCL-a u početnoj dozi od> 300mg/m2 na dan ili onkoloških indikacija bez CTCL-a.
Additional adverse reactions observed when used outside of the recommended dose and indication i.e. used in CTCL at an initial dose> 300mg/m2/day or in non-CTCL cancer indications.

Nuspojave opažene tijekom liječenja hepatitisa C odgovaraju onima koje su prijavljene pri primjeni lijeka IntronA u drugim indikacijama, uz očekivano povećanje incidencije vezano uz dozu.
The undesirable effects seen with hepatitis C are representative of those reported when IntronA is administered in other indications, with some anticipated dose-related increases in incidence.

Hematološke nuspojave opažene u kliničkim ispitivanjima lijeka Xofigo imaju puno manju učestalost i težinu nego što bi se moglo očekivati s obzirom na izračunate apsorbirane doze za crvenu koštanu srž.
The haematological adverse reactions observed in the clinical studies with Xofigo are much lower in frequency and severity than what could be expected from the calculated absorbed doses to the red marrow.

Nuspojave opažene u objedinjenim ključnim kliničkim ispitivanjima faze 3 alogliptina kao monoterapije ili kao dodatne kombinirane terapije, koja su uključivala ukupno 5, 659 bolesnika, navedene su u nastavku tablica 1.
In the pooled pivotal phase 3 controlled clinical trials of alogliptin as monotherapy and as add-on combination therapy involving 5,659 patients, the observed adverse reactions are listed below Table 1.

Klinički značajne nuspojave opažene u studijama CAPRIE(uspoređivan je sam klopidogrel prema acetilsalicilatnoj kiselini) te CURE, CLARITY i COMMIT(uspoređivan je klopidogrel plus ASK prema samoj ASK) opisane su u daljnjem tekstu.
The clinically relevant adverse reactions observed in four major studies, the CAPRIE study(a study comparing clopidogrel alone to ASA) and the CURE, CLARITY and COMMIT studies(studies comparing clopidogrel plus ASA to ASA alone) are discussed below.

Klinički značajne nuspojave opažene u četiri velika ispitivanja, odnosno CAPRIE(usporedba klopidogrela u monoterapiji i ASK) te CURE, CLARITY i COMMIT(usporedba klopidogrela uz ASK s ASK u monoterapiji) koja su opisana u daljnjem tekstu.
The clinically relevant adverse reactions observed in four major studies, the CAPRIE study(a study comparing clopidogrel alone to ASA) and the CURE, CLARITY and COMMIT studies(studies comparing clopidogrel plus ASA to ASA alone) are discussed below.